A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Titel:
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Auteur:
Piha-Paul, Sarina A. Tseng, Chieh Tran, Hai T. Gao, Meng Karp, Daniel D. Subbiah, Vivek Tsimberidou, Apostolia Maria Kawedia, Jitesh D. Fu, Siqing Pant, Shubham Yap, Timothy A. Morris, Van K. Kee, Bryan K. Blum Murphy, Mariela Lim, JoAnn Meric-Bernstam, Funda